Clustering of transcriptional profiles identifies changes to insulin signaling as an early event in a mouse model of Alzheimer's disease

BMC Genomics

Volumn 14, Issue 1, 2013, Pages

  Jackson, Harriet M ^a   Soto, Ileana ^a   Graham, Leah C ^a,b   Carter, Gregory W ^a   Howell, Gareth R ^a,b  

^a JACKSON LABORATORY   (United States)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INSULIN; INSULIN RECEPTOR SUBSTRATE; IRS4 PROTEIN, MOUSE; OXYTOCIN; TRANSCRIPTOME;

AGE; ALZHEIMER DISEASE; AMYLOID PLAQUE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APPETITE; ARTICLE; CONTROLLED STUDY; DEPRESSION; DOWN REGULATION; FEMALE; GENE; GENE EXPRESSION; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; IRS4 GENE; METABOLISM; MOUSE; NONHUMAN; OXIDATIVE PHOSPHORYLATION; PHENOTYPE; QUALITY CONTROL; RIBOSOME; RNA ISOLATION; SEQUENCE ALIGNMENT; SIGNAL TRANSDUCTION; SURGICAL TECHNIQUE; ANIMAL; BRAIN CORTEX; C57BL MOUSE; CLUSTER ANALYSIS; DISEASE MODEL; GENETIC TRANSCRIPTION; GENETICS; HUMAN; HYPOPHYSIS ADRENAL SYSTEM; HYPOTHALAMUS HYPOPHYSIS SYSTEM; PHYSIOLOGY;

MUS;

ALZHEIMER DISEASE; ANIMALS; CEREBRAL CORTEX; CLUSTER ANALYSIS; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; HYPOTHALAMO-HYPOPHYSEAL SYSTEM; INSULIN; INSULIN RECEPTOR SUBSTRATE PROTEINS; MICE; MICE, INBRED C57BL; OXYTOCIN; PHENOTYPE; PITUITARY-ADRENAL SYSTEM; SIGNAL TRANSDUCTION; TRANSCRIPTION, GENETIC; TRANSCRIPTOME;

EID: 84888093231     PISSN: None     EISSN: 14712164     Source Type: Journal    
DOI: 10.1186/1471-2164-14-831     Document Type: Article

References (79)

1. Bero AW, Yan P, Roh JH, Cirrito JR, Stewart FR, Raichle ME, Lee JM, Holtzman DM. Neuronal activity regulates the regional vulnerability to amyloid-beta deposition. Nat Neurosci 2011, 14(6):750-756. 10.1038/nn.2801, 3102784, 21532579.
2. Jankowsky JL, Fadale DJ, Anderson J, Xu GM, Gonzales V, Jenkins NA, Copeland NG, Lee MK, Younkin LH, Wagner SL, et al. Mutant presenilins specifically elevate the levels of the 42 residue beta-amyloid peptide in vivo: evidence for augmentation of a 42-specific gamma secretase. Hum Mol Genet 2004, 13(2):159-170.
3. Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 1991, 82(4):239-259. 10.1007/BF00308809, 1759558.
4. Sisodia SS, Price DL. Role of the beta-amyloid protein in Alzheimer's disease. FASEB journal: official publication of the Federation of American Societies for Experimental Biology 1995, 9(5):366-370.
5. Price DL, Sisodia SS, Gandy SE. Amyloid beta amyloidosis in Alzheimer's disease. Curr Opin Neurol 1995, 8(4):268-274. 10.1097/00019052-199508000-00004, 7582041.
6. Baglietto-Vargas D, Moreno-Gonzalez I, Sanchez-Varo R, Jimenez S, Trujillo-Estrada L, Sanchez-Mejias E, Torres M, Romero-Acebal M, Ruano D, Vizuete M, et al. Calretinin interneurons are early targets of extracellular amyloid-beta pathology in PS1/AbetaPP Alzheimer mice hippocampus. J Alzheimer's Disease 2010, 21(1):119-132.
7. Adalbert R, Nogradi A, Babetto E, Janeckova L, Walker SA, Kerschensteiner M, Misgeld T, Coleman MP. Severely dystrophic axons at amyloid plaques remain continuous and connected to viable cell bodies. Brain 2009, 132(Pt 2):402-416.
8. Tanzi RE. The synaptic Abeta hypothesis of Alzheimer disease. Nat Neurosci 2005, 8(8):977-979. 10.1038/nn0805-977, 16047022.
9. Sloane PD, Zimmerman S, Suchindran C, Reed P, Wang L, Boustani M, Sudha S. The public health impact of Alzheimer's disease, 2000-2050: potential implication of treatment advances. Annu Rev Publ Health 2002, 23:213-231.
10. Norton S, Matthews F, Brayne C. A commentary on studies presenting projections of the future prevalence of dementia. BMC Public Health 2013, 13(1):1. 10.1186/1471-2458-13-1, 3547813, 23280303.
11. Extance A. Alzheimer's failure raises questions about disease-modifying strategies. Nat Rev Drug Discov 2010, 9(10):749-751. 10.1038/nrd3288, 20885394.
12. Karran E, Mercken M, Strooper BD. The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics. Nat Rev Drug Discov 2011, 10(9):698-712. 10.1038/nrd3505, 21852788.
13. Schor NF. What the halted phase III γ-secretase inhibitor trial may (or may not) be telling us. Ann Neurol 2011, 69(2):237-239. 10.1002/ana.22365, 21387368.
14. Grundman M, Dibernardo A, Raghavan N, Krams M, Yuen E. A watershed year for Alzheimer's disease research. J Nutr Health Aging 2012, 17(1):51-53.
15. Sperling R, Salloway S, Brooks DJ, Tampieri D, Barakos J, Fox NC, Raskind M, Sabbagh M, Honig LS, Porsteinsson AP, et al. Amyloid-related imaging abnormalities in patients with Alzheimer's disease treated with bapineuzumab: a retrospective analysis. Lancet Neurol 2012, 11(3):241-249. 10.1016/S1474-4422(12)70015-7, 22305802.
16. Cowley T, González-Reyes R, Richardson J, Virley D, Upton N, Lynch M. The Age-related gliosis and accompanying deficit in spatial learning are unaffected by dimebon. Neurochem Res 2013, 38(6):1190-1195. 10.1007/s11064-012-0884-0, 23011205.
17. Tanzi RE. The genetics of Alzheimer disease. Cold Spring Harbor Perspectives in Medicine 2012, 2(10). doi: 10.1101/cshperspect.a006296.
18. Price DL, Sisodia SS. Mutant genes in familial alzheimer's disease and transgenic models. Annu Rev Neurosci 1998, 21(1):479-505. 10.1146/annurev.neuro.21.1.479, 9530504.
19. Rossor MN, Iversen LL, Reynolds GP, Mountjoy CQ, Roth M. Neurochemical characteristics of early and late onset types of Alzheimer's disease. Br Med J 1984, 288(6422):961-964.
20. Kamboh MI. Molecular genetics of late-onset Alzheimer's disease. Ann Hum Genet 2004, 68(4):381-404. 10.1046/j.1529-8817.2004.00110.x, 15225164.
21. Duara R, Lopez-Alberola RF, Barker WW, Loewenstein DA, Zatinsky M, Eisdorfer CE, Weinberg GB. A comparison of familial and sporadic Alzheimer's disease. Neurology 1993, 43(7):1377. 10.1212/WNL.43.7.1377, 8327141.
22. Bertram L, Tanzi RE. The genetics of Alzheimer's disease. Progress in molecular biology and translational science 2012, 107:79-100.
23. Kang J, Lemaire H-G, Unterbeck A, Salbaum JM, Masters CL, Grzeschik K-H, Multhaup G, Beyreuther K, Muller-Hill B. The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor. Nature 1987, 325(6106):733-736. 10.1038/325733a0, 2881207.
24. Tanzi R, Gusella J, Watkins P, Bruns G, St George-Hyslop P, Van Keuren M, Patterson D, Pagan S, Kurnit D, Neve R. Amyloid beta protein gene: cDNA, mRNA distribution, and genetic linkage near the Alzheimer locus. Science 1987, 235(4791):880-884. 10.1126/science.2949367, 2949367.
25. Tanzi RE, McClatchey AI, Lamperti ED, Villa-Komaroff L, Gusella JF, Neve RL. Protease inhibitor domain encoded by an amyloid protein precursor mRNA associated with Alzheimer's disease. Nature 1988, 331(6156):528-530. 10.1038/331528a0, 2893290.
26. Genin E, Hannequin D, Wallon D, Sleegers K, Hiltunen M, Combarros O, Bullido MJ, Engelborghs S, De Deyn P, Berr C, et al. APOE and Alzheimer disease: a major gene with semi-dominant inheritance. Mol Psychiatr 2011, 16(9):903-907.
27. Bullido MJ, Artiga MJ, Recuero M, Sastre I, Garcia MA, Aldudo J, Lendon C, Han SW, Morris JC, Frank A, et al. A polymorphism in the regulatory region of APOE associated with risk for Alzheimer's dementia. Nat Genet 1998, 18(1):69-71. 10.1038/ng0198-69, 9425904.
28. Pievani M, Galluzzi S, Thompson PM, Rasser PE, Bonetti M, Frisoni GB. APOE4 is associated with greater atrophy of the hippocampal formation in Alzheimer's disease. Neuroimage 2011, 55(3):909-919. 10.1016/j.neuroimage.2010.12.081, 21224004.
29. Goedert M. Tau protein and the neurofibrillary pathology of Alzheimer's disease. Trends Neurosci 1993, 16(11):460-465. 10.1016/0166-2236(93)90078-Z, 7507619.
30. Kidd M. Paired helical filaments in electron microscopy of Alzheimer's Disease. Nature 1963, 197(4863):192-193.
31. Gilley J, Adalbert R, Coleman MP. Modelling early responses to neurodegenerative mutations in mice. Biochem Soc Trans 2011, 39(4):933-938. 10.1042/BST0390933, 21787326.
32. Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002, 297(5580):353-356. 10.1126/science.1072994, 12130773.
33. Ghiso J, Frangione B. Amyloidosis and Alzheimer's disease. Adv Drug Deliv Rev 2002, 54(12):1539-1551. 10.1016/S0169-409X(02)00149-7, 12453671.
34. Rodriguez JJ, Olabarria M, Chvatal A, Verkhratsky A. Astroglia in dementia and Alzheimer's disease. Cell Death Differ 2008, 16(3):378-385.
35. Cohen E, Paulsson JF, Blinder P, Burstyn-Cohen T, Du D, Estepa G, Adame A, Pham HM, Holzenberger M, Kelly JW, et al. Reduced IGF-1 signaling delays age-associated proteotoxicity in mice. Cell 2009, 139(6):1157-1169. 10.1016/j.cell.2009.11.014, 3017511, 20005808.
36. Wyss-Coray T, Rogers J. Inflammation in alzheimer disease - a brief review of the basic science and clinical literature. Cold Spring Harb Perspect Med 2012, 2(1). doi: 10.1101/cshperspect.a006346.
37. Tuppo EE, Arias HR. The role of inflammation in Alzheimer's disease. Int J Biochem Cell Biol 2005, 37(2):289-305. 10.1016/j.biocel.2004.07.009, 15474976.
38. Akiyama H, Barger S, Barnum S, Bradt B, Bauer J, Cole GM, Cooper NR, Eikelenboom P, Emmerling M, Fiebich BL, et al. Inflammation and Alzheimer's disease. Neurobiol Aging 2000, 21(3):383-421. 10.1016/S0197-4580(00)00124-X, 10858586.
39. Howell GR, Macalinao DG, Sousa GL, Walden M, Soto I, Kneeland SC, Barbay JM, King BL, Marchant JK, Hibbs M, et al. Molecular clustering identifies complement and endothelin induction as early events in a mouse model of glaucoma. J Clin Invest 2011, 121(4):1429-1444. 10.1172/JCI44646, 3069778, 21383504.
40. Howell GR, Soto I, Zhu X, Ryan M, Macalinao DG, Sousa GL, Caddle LB, MacNicoll KH, Barbay JM, Porciatti V, et al. Radiation treatment inhibits monocyte entry into the optic nerve head and prevents neuronal damage in a mouse model of glaucoma. J Clin Invest 2012, 122(4):1246-1261. 10.1172/JCI61135, 3314470, 22426214.
41. Howell GR, Walton DO, King BL, Libby RT, John SW. Datgan, a reusable software system for facile interrogation and visualization of complex transcription profiling data. BMC Genom 2011, 12:429.
42. Meyer-Luehmann M, Spires-Jones TL, Prada C, Garcia-Alloza M, de Calignon A, Rozkalne A, Koenigsknecht-Talboo J, Holtzman DM, Bacskai BJ, Hyman BT. Rapid appearance and local toxicity of amyloid-beta plaques in a mouse model of Alzheimer's disease. Nature 2008, 451(7179):720-724. 10.1038/nature06616, 3264491, 18256671.
43. Garcia-Alloza M, Robbins EM, Zhang-Nunes SX, Purcell SM, Betensky RA, Raju S, Prada C, Greenberg SM, Bacskai BJ, Frosch MP. Characterization of amyloid deposition in the APPswe/PS1dE9 mouse model of Alzheimer disease. Neurobiol Dis 2006, 24(3):516-524. 10.1016/j.nbd.2006.08.017, 17029828.
44. Malm TM, Iivonen H, Goldsteins G, Keksa-Goldsteine V, Ahtoniemi T, Kanninen K, Salminen A, Auriola S, Van Groen T, Tanila H, et al. Pyrrolidine dithiocarbamate activates Akt and improves spatial learning in APP/PS1 mice without affecting beta-amyloid burden. J Neurosci 2007, 27(14):3712-3721. 10.1523/JNEUROSCI.0059-07.2007, 17409235.
45. Trapnell C, Pachter L, Salzberg SL. TopHat: discovering splice junctions with RNA-Seq. Bioinformatics 2009, 25(9):1105-1111. 10.1093/bioinformatics/btp120, 2672628, 19289445.
46. Trapnell C, Williams BA, Pertea G, Mortazavi A, Kwan G, van Baren MJ, Salzberg SL, Wold BJ, Pachter L. Transcript assembly and quantification by RNA-Seq reveals unannotated transcripts and isoform switching during cell differentiation. Nat Biotech 2010, 28(5):511-515.
47. Sohal RS, Mockett RJ, Orr WC. Mechanisms of aging: an appraisal of the oxidative stress hypothesis. Free Radic Biol Med 2002, 33(5):575-586. 10.1016/S0891-5849(02)00886-9, 12208343.
48. Lesnefsky EJ, Hoppel CL. Oxidative phosphorylation and aging. Ageing Res Rev 2006, 5(4):402-433. 10.1016/j.arr.2006.04.001, 16831573.
49. Shigenaga MK, Hagen TM, Ames BN. Oxidative damage and mitochondrial decay in aging. Proc Natl Acad Sci 1994, 91(23):10771-10778. 10.1073/pnas.91.23.10771, 45108, 7971961.
50. Swerdlow RH, Burns JM, Khan SM. The Alzheimer's disease mitochondrial cascade hypothesis. J Alzheimers Dis 2010, 20:265-279.
51. Rattan SIS. Synthesis, modifications, and turnover of proteins during aging. Exp Gerontol 1996, 31(1-2):33-47.
52. Brewer G. Messenger RNA decay during aging and development. Ageing Res Rev 2002, 1(4):607-625. 10.1016/S1568-1637(02)00023-5, 12208236.
53. Dröge W, Schipper HM. Oxidative stress and aberrant signaling in aging and cognitive decline. Aging Cell 2007, 6(3):361-370. 10.1111/j.1474-9726.2007.00294.x, 1974775, 17517043.
54. Balaban RS, Nemoto S, Finkel T. Mitochondria, oxidants, and aging. Cell 2005, 120(4):483-495. 10.1016/j.cell.2005.02.001, 15734681.
55. Vidoni ED, Townley RA, Honea RA, Burns JM, Initiative FtAsDN Alzheimer disease biomarkers are associated with body mass index. Neurology 2011, 77(21):1913-1920. 10.1212/WNL.0b013e318238eec1, 3233188, 22105948, Initiative FtAsDN.
56. Loskutova N, Honea RA, Brooks WM, Burns JM. Reduced limbic and hypothalamic volumes correlate with bone density in early Alzheimer's disease. J Alzheimers Dis 2010, 20(1):313-322. 2892930, 20164583.
57. Iacono RP, Sandyk R. Alzheimer's disease and the pivotal role of the hypothalamus and the intrinsic opioid system. Int J Neurosci 1987, 32(3-4):710-714.
58. Killick R, Scales G, Leroy K, Causevic M, Hooper C, Irvine EE, Choudhury AI, Drinkwater L, Kerr F, Al-Qassab H, et al. Deletion of Irs2 reduces amyloid deposition and rescues behavioural deficits in APP transgenic mice. Biochem Biophys Res Comm 2009, 386(1):257-262. 10.1016/j.bbrc.2009.06.032, 2726921, 19523444.
59. Schubert M, Brazil DP, Burks DJ, Kushner JA, Ye J, Flint CL, Farhang-Fallah J, Dikkes P, Warot XM, Rio C, et al. Insulin receptor substrate-2 deficiency impairs brain growth and promotes tau phosphorylation. J Neurosci 2003, 23(18):7084-7092.
60. Numan S, Russell DS. Discrete expression of insulin receptor substrate-4 mRNA in adult rat brain. Brain research Molecular brain research 1999, 72(1):97-102. 10.1016/S0169-328X(99)00160-6, 10521603.
61. Li JY, Chai B, Zhang W, Wu X, Zhang C, Fritze D, Xia Z, Patterson C, Mulholland MW. Ankyrin repeat and SOCS box containing protein 4 (Asb-4) colocalizes with insulin receptor substrate 4 (IRS4) in the hypothalamic neurons and mediates IRS4 degradation. BMC Neurosci 2011, 12:95. 10.1186/1471-2202-12-95, 3192677, 21955513.
62. Flurkey KM, Currer J, Harrison DE. Chapter 20 - Mouse Models in Aging Research. The Mouse in Biomedical Research (Second Edition) 2007, 637-672. Burlington: Academic Press, James GF, Muriel TD, Fred WQ, Stephen WB, Christian EN, Abigail SL.
63. Aznar S, Knudsen GM. Depression and Alzheimer's disease: is stress the initiating factor in a common neuropathological cascade?. J Alzheimer's Disease 2011, 23(2):177-193.
64. Gracia-Garcia P, De-la-Camara C, Santabarbara J, Lopez-Anton R, Quintanilla MA, Ventura T, Marcos G, Campayo A, Saz P, Lyketsos C, et al. Depression and incident alzheimer disease: the impact of disease severity. Am J Geriatr Psychiatry 2013, doi: 10.1016/j.jagp.2013.02.011.
65. Swaab DF, Bao AM, Lucassen PJ. The stress system in the human brain in depression and neurodegeneration. Ageing Res Rev 2005, 4(2):141-194. 10.1016/j.arr.2005.03.003, 15996533.
66. Wilson RS, Arnold SE, Schneider JA, Kelly JF, Tang Y, Bennett DA. Chronic psychological distress and risk of Alzheimer's disease in old age. Neuroepidemiology 2006, 27(3):143-153. 10.1159/000095761, 16974109.
67. Burbach JPH, Voorhuis TAM, van Tol HHM, Ivell R. In situ hybridization of oxytocin messenger RNA: Macroscopic distribution and quantitation in rat hypothalamic cell groups. Biochem Biophys Res Commun 1987, 145(1):10-14. 10.1016/0006-291X(87)91280-0, 3593333.
68. Rodriguez EM, Blazquez JL, Guerra M. The design of barriers in the hypothalamus allows the median eminence and the arcuate nucleus to enjoy private milieus: the former opens to the portal blood and the latter to the cerebrospinal fluid. Peptides 2010, 31(4):757-776. 10.1016/j.peptides.2010.01.003, 20093161.
69. Ciofi P, Garret M, Lapirot O, Lafon P, Loyens A, Prévot V, Levine JE. Brain-endocrine interactions: a microvascular route in the mediobasal hypothalamus. Endocrinology 2009, 150(12):5509-5519. 10.1210/en.2009-0584, 2819742, 19837874.
70. Krisch B, Leonhardt H. The functional and structural border of the neurohemal region of the median eminence. Cell Tissue Res 1978, 192(2):327-339.
71. O'Neill C, Kiely AP, Coakley MF, Manning S, Long-Smith CM. Insulin and IGF-1 signalling: longevity, protein homoeostasis and Alzheimer's disease. Biochem Soc Trans 2012, 40(4):721-727. 10.1042/BST20120080, 22817723.
72. de la Monte SM. Brain insulin resistance and deficiency as therapeutic targets in Alzheimer's disease. Curr Alzheimer Res 2012, 9(1):35-66. 10.2174/156720512799015037, 3349985, 22329651.
73. Naderali EK, Ratcliffe SH, Dale MC. Review: obesity and Alzheimer's disease: a link between body weight and cognitive function in old age. Am J Alzheimers Dis Other Demen 2009, 24(6):445-449. 10.1177/1533317509348208, 19801534.
74. Hildreth KL, Van Pelt RE, Schwartz RS. Obesity, insulin resistance, and Alzheimer's disease. Obesity 2012, 20(8):1549-1557. 10.1038/oby.2012.19, 22310232.
75. Bartke A. Impact of reduced insulin-like growth factor-1/insulin signaling on aging in mammals: novel findings. Aging Cell 2008, 7(3):285-290. 10.1111/j.1474-9726.2008.00387.x, 18346217.
76. Sano H, Liu SC, Lane WS, Piletz JE, Lienhard GE. Insulin receptor substrate 4 associates with the protein IRAS. J Biol Chem 2002, 277(22):19439-19447. 10.1074/jbc.M111838200, 11912194.
77. Cataldo AM, Hamilton DJ, Barnett JL, Paskevich PA, Nixon RA. Properties of the endosomal-lysosomal system in the human central nervous system: disturbances mark most neurons in populations at risk to degenerate in Alzheimer's disease. J Neurosci 1996, 16(1):186-199.
78. Cataldo AM, Peterhoff CM, Troncoso JC, Gomez-Isla T, Hyman BT, Nixon RA. Endocytic pathway abnormalities precede amyloid beta deposition in sporadic Alzheimer's disease and Down syndrome: differential effects of APOE genotype and presenilin mutations. Am J Pathol 2000, 157(1):277-286. 10.1016/S0002-9440(10)64538-5, 1850219, 10880397.
79. Tsuruzoe K, Emkey R, Kriauciunas KM, Ueki K, Kahn CR. Insulin receptor substrate 3 (IRS-3) and IRS-4 impair IRS-1- and IRS-2-mediated signaling. Mol Cell Biol 2001, 21(1):26-38. 10.1128/MCB.21.1.26-38.2001, 86565, 11113178.